



AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment

This is the author's manuscript	
Original Citation:	
Availability:	
This version is available http://hdl.handle.net/2318/150103	since 2016-07-14T13:11:32Z
Published version:	
DOI:10.1016/j.ejpb.2014.10.017	
Terms of use:	
Open Access	
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.	

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by agreement between Elsevier and the University of Turin. Changes resulting from the publishing process - such as editing, corrections, structural formatting, and other quality control mechanisms - may not be reflected in this version of the text. The definitive version of the text was subsequently published in EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 88, 2014, 10.1016/j.ejpb.2014.10.017.

You may download, copy and otherwise use the AAM for non-commercial purposes provided that your license is limited by the following restrictions:

- (1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND license.
- (2) The integrity of the work and identification of the author, copyright owner, and publisher must be preserved in any copy.
- (3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en), 10.1016/j.ejpb.2014.10.017

The definitive version is available at: http://linkinghub.elsevier.com/retrieve/pii/S0939641114003166

- 1 **Title**: Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma
- 2 treatment.
- 3 **Author names and affiliations**: Daniela Chirio^a, Marina Gallarate^a, Elena Peira^a, Luigi Battaglia^a,
- 4 Elisabetta Muntoni^a, Chiara Riganti^b, Elena Biasibetti^c, Maria Teresa Capucchio^c, Alberto Valazza^c,
- 5 Pierpaolo Panciani^d, Michele Lanotte^d, Laura Annovazzi^e, Valentina Caldera^e, Marta Mellai^e,
- 6 Gaetano Filice^f, Silvia Corona^f, Davide Schiffer^e
- 7 ^a University of Turin, Dipartimento di Scienza e Tecnologia del Farmaco, via Giuria 9, 10125
- 8 Torino, Italy.
- 9 <u>daniela.chirio@unito.it</u>, <u>marina.gallarate@unito.it</u>, <u>elena.peira@unito.it</u>, <u>luigi.battaglia@unito.it</u>,
- 10 elisabetta.muntoni@unito.it
- ^b University of Turin, Dipartimento di Oncologia, Regione Gonzole 10, 10043 Orbassano (TO),
- 12 Italy.
- 13 chiara.riganti@unito.it
- ^c University of Turin, Dipartimento di Scienze Veterinarie, Largo Paolo Braccini 2, 10095
- 15 Grugliasco (TO), Italy.
- 16 <u>elena.biasibetti@unito.it, mariateresa.capucchio@unito.it, alberto.valazza@unito.it</u>
- d University of Turin, Dipartimento di Neuroscienze, Via Cherasco 15, 10126 Torino, Italy.
- 18 <u>vincy.bip@alice.it</u>, <u>michele.lanotte@unito.it</u>
- ^e Policlinico di Monza, Centro di NeuroBioOncologia, Via Pietro Micca 29, 13100 Vercelli, Italy.
- 20 davide.schiffer@unito.it, laura.annovazzi@cnbo.it, valentina.caldera@cnbo.it,
- 21 marta.mellai@cnbo.it
- ^f IRCCS Policlinico San Matteo, University of Pavia, Dipartimento di Malattie Infettive, V.le Golgi
- 23 19, 27100 Pavia, Italy,
- 24 gaetano.filice@unipv.it

- 27 Corresponding Author: Daniela Chirio, via P. Giuria 9, 10125 Torino, Italy
- daniela.chirio@unito.it
- 29 Phone: +39 0116707668 Fax: +39 0116707687

31

Abstract

- 32 Paclitaxel loaded solid lipid nanoparticles (SLN) of behenic acid were prepared with the
- coacervation technique. Generally, spherical shaped SLN with mean diameters in the range 300-600
- 34 nm were obtained. The introduction of charged molecules, such as stearylamine and glycol chitosan
- into the formulation allowed to obtain positive SLN with Zeta potential in the 8-20 mV range and
- encapsulation efficiency in the 25-90% range.
- 37 Blood-brain barrier (BBB) permeability, tested in vitro through hCMEC/D3 cells monolayer,
- 38 showed a significantly increase in the permeation of Coumarin-6, used as model drug, when
- vehicled in SLN. Positive-charged SLN do not seem to enhance permeation although stearylamine-
- 40 positive SLN resulted the best permeable formulation after 24 h.
- 41 Cytotoxicity studies on NO3 glioblastoma cell line demonstrated the maintenance of cytotoxic
- 42 activity of all paclitaxel-loaded SLN that was always unmodified or greater compared with free
- drug. No difference in cytotoxicity was noted between neutral and charged SLN.
- 44 Co-culture experiments with hCMEC/D3 and different glioblastoma cells evidenced that, when
- delivered in SLN, paclitaxel increased its cytotoxicity towards glioblastoma cells.

- 47 Abbreviations:
- 48 PTX, paclitaxel; SLN, solid lipid nanoparticles; BA, behenic acid; ST, stearylamine; GCS, glycol
- 49 chitosan; BBB, blood-brain barrier; GBM, blioblastoma multiforme; CNS, central nervous system;
- 50 NP, nanoparticles; cationic bovine serum albumin, CBSA; NHEJ, non-homologous end joining;
- 51 PK, protein Kinase; CS, chitosan; Cou-6, coumarin 6; Na-BA, sodium behenate; CHOL,
- 52 cholesterol; FD, freeze-dried; DMEM, Dulbecco's modified Eagle's medium; NS, neurosphere;

- AC, adherent cell; ATM, ataxia telangiectasia mutated; ChK2, checkpoint kinase; p-53BP1, 53
- 54 binding protein 1; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl-tetrazolium bromide; IF,
- 55 immunofluorescence; HR, homologous recombination; TEM, transmission electron microscopy;
- EE, entrapment efficiency; Pgp, P-glycoprotein; MRP1, multidrug resistance related protein 1.

58 Keywords: paclitaxel, SLN, coacervation, BBB permeability, cytotoxicity, glioblastoma

- 60 Chemical compounds studied in this article:
- 61 Paclitaxel (PubChem CID: 36314)
- 62 Coumarin-6 (PubChem CID: 100334)
- 63 Behenic acid (PubChem CID: 8215)

1. Introduction

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

Glioblastoma multiforme (GBM) is the most common form of primary brain tumor in the central nervous system (CNS); its aggressive nature and evasiveness to treatments make it one of the most lethal cancers [1]. Current treatments for GBM provide a tumor surgical resection followed by pharmacotherapy and radiotherapy. Pharmacotherapy, directed by residual tumor cells elimination, ranges from common chemotherapeutic agents such as temozolomide to more recent antiangiogenic agents and immunotherapeutic treatments [2]. However, anti-cancer therapeutic agents have not significantly increased the median survival of GBM patients over the past 10 years. The 5year survival rate of GBM patients after treatment that includes surgical resection, radiation and chemotherapy, is 9.8%. The failure of chemotherapy is due to the inability of intravenously administered anticancer agents to reach the brain parenchyma. An endothelial cell monolayer associated with pericytes and astrocytes, known as the blood-brain barrier (BBB), separates blood from the cerebral parenchyma and prevents the penetration of drugs into the CNS. BBB is a functional unit composed by the peculiar endothelium of brain microvessels, the capillary basal lamina and the surrounding astrocytes, neurons, microglial cells and pericytes, which contribute to the maintenance of the barrier properties [3, Figure A.1]. The presence of tight junctions and adherent junctions between adjacent endothelial cells [4], the lack of fenestrations and pinocytotic vesicles [5], the abundance of efflux transporters belonging to the ATP binding cassette family on the endothelium luminal side [6] account for the low delivery of drugs, such as antineoplastic agents [7], from the bloodstream to the brain parenchima. Various invasive strategies have been developed to improve the penetration of drugs into the brain [8]. Traditional approach to overcome brain drug delivery obstacles includes direct intracerebral drug injection [9], which is associated with a high risk for the patient. Less invasive strategies have also been investigated. One approach consists in generating a transient disruption of BBB in conjunction with the systemic administration of anticancer agents. The

intracarotid administration of a hyperosmotic solution such as mannitol led to a rapid diffusion of 90 fluid across the cerebral endothelium, moving out of the endothelial cells into the vascular lumen 91 and inducing the opening of the tight junctions for a few hours [10]. 92 93 Another approach concerns the modification of drugs in order to make them more lipophilic, improving their penetration into the brain by passive diffusion. Lipophilic analogs and prodrugs 94 were thus developed [11]. 95 A more recent strategy to deliver drugs to the brain is the use of colloidal polymers to form 96 97 nanometer sized carriers [12]. The basic reason of common acceptance of these vehicles is due to their drug release controlled profile of as well as to their selected targeting mechanism. Targeting 98 action may be due to the steric hindrance created by nano-vectors: after parenteral administration, 99 due to steric phenomenon they conceal themselves from opsonization event induced by tissue 100 macrophages. By this way they achieve targeting ability to the brain and partially avoid other 101 102 reticuloendothelial system organs like liver, spleen, etc [13]. From the last few decades, nanoparticles (NP) have attracted considerable interest in targeting drug 103 104 molecules to the brain [14]. The correct mechanism of barrier opening by NP is not exactly known; the delivered NP enter into the brain by crossing the BBB by various endocytotic mechanisms, as 105 polymeric albumin or poly(butylcyanoacrylate) NP are reported to enter into the brain by their small 106 size mediated endocytosis [15,16]. An increased drug retention in brain blood capillaries combined 107 with an adsorption to capillary can increase drug transport due to an enhanced concentration 108 gradient; an increase of BBB fluidization, an opening of tight junctions between endothelial, an 109 inhibition of the P-glycoprotein efflux system are other possible mechanisms that can increase brain 110 111 drug concentration [17]. Although NP may be designed to entrap high molecular weight or hydrophilic therapeutics, BBB 112 retardation of drug NP entrapped is based on NP characteristics and not on the therapeutic agent 113 [18]. 114

Indeed, poly(butyl cyanoacrylate) NP overcoated with 1% polysorbate 80 have been experimentally successful as brain drug delivery for doxorubicin [19] and dalargin [20], poly(lactic-co-glycolic acid) and cetyl alcohol/polysorbate NP for paclitaxel brain delivery [21,22]. In addition to BBB functional characteristics limiting permeation, brain microvasculature endothelia also present a luminal electrostatic barrier at physiologic pH. The negative electrostatic charge is created by surface expression and adhesion of the glycocalyx residues: proteoglycans, sulfated mucopolysaccharides, and sulfated and sialic acid-containing glycoproteins and glycolipids [23]. Cationic molecules have been shown to occupy anionic areas at the BBB endothelium [24] and increase BBB permeability via a presumed tight junction disruption [25]. Recent in vitro reports have demonstrated that positive-charged NP have an increased brain distribution compared to anionic and neutral NP [26]. However, there is little data regarding brain permeability of positive-charged NP. Lu et al. [27] developed and evaluated cationic bovine serum albumin (CBSA) conjugated with poly(ethyleneglycol)-poly(lactide) NP (CBSA-NP). To evaluate the effects of brain delivery, BSA conjugated with pegylated NP (BSA-NP) was used as the control group and Coumarin-6 was incorporated into the NP as the fluorescent probe. The qualitative and quantitative results of CBSA-NP uptake experiment compared with those of BSA-NP showed that rat brain capillary endothelial cells took in much more CBSA-NP than BSA-NP at 37 °C, at different concentrations and time incubations. After a dose of 60 mg/kg CBSA-NP or BSA-NP injection in mice caudal vein, fluorescent microscopy of brain coronal sections showed a higher accumulation of CBSA-NP in the lateral ventricle, third ventricle and periventricular region than that of BSA-NP. In an experimental work Lockman et al. [15] evaluated the effect of neutral, anionic and cationic charged NP on BBB integrity and NP brain permeability. Neutral NP and low concentrations of anionic NP had no effect on BBB integrity, whereas, high concentrations of anionic NP and cationic NP disrupted the BBB. The brain uptake rates of anionic NP at lower concentrations were higher than of neutral or cationic formulations at the same concentrations.

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

In literature, many authors studied solid lipid nanoparticles (SLN) as drug delivery systems to 140 141 deliver drugs to the CNS [28,29]. SLN are disperse systems having size ranging from 1 to 1000 nm which represent an alternative to polymeric particulate carriers and are composed of physiological 142 or biocompatible lipids or lipid molecules with a history of safe use in therapy and are generally 143 suitable for intravenous administration. 144 As few data are present in literature about positive-charged SLN for brain delivery, the purpose of 145 this work will be to prepare, characterize and evaluate in vitro the potential of positive-charged SLN 146 to vehicle paclitaxel (PTX) to the brain for GBM treatment. 147 PTX, a diterpene isolated from *Taxus brevifolia*, is one of the most active chemotherapeutic agents 148 149 against a wide panel of solid tumors including urothelial, breast, lung, and ovarian cancers. It has been demonstrated that PTX is effective against glioblastoma cells in vitro [30,31], however its 150 151 clinical use is limited due to its poor BBB penetration capability and drug-resistance [32,33]. 152 Due to its low water solubility, PTX is formulated in a mixture of Cremophor® EL and dehydrated ethanol (50:50 v/v) a combination known as Taxol®. However, Taxol® has some severe side 153 154 effects related to Cremophor® EL and ethanol [34]. Therefore, there is an urgent need for the development of alternative PTX formulations. 155 Recently, a new solvent-free technique, defined as "coacervation", was developed to prepare fatty 156 acids-based SLN [35]. Briefly, a fatty acid alkaline salt micellar solution in the presence of an 157 appropriate polymeric stabilizer was prepared; when the pH is lowered by acidification, the fatty 158 acid precipitates as nanoparticles owing to proton exchange between the acid solution and the 159 sodium salt. 160 SLN were prepared using two different positive-charged substances: ST or GCS. ST possess a 161 hydrocarbonic chain that can probably be incorporated within the lipid matrix, while its positive 162 charge is exposed to the external surface. GCS, a chitosan derivative conjugated with ethylene 163 glycol branches, is a water soluble at a neutral/acidic pH values polymer whose pendant glycol 164 branches increase both the aqueous solubility of the native chitosan (CS) and provide steric 165

stabilization [36]. Mao et al [37] have established that CS is capable of opening the tight junctions of epithelial cells and it can improve the uptake of hydrophilic drugs including peptides.

For the above mentioned purpose, PTX loaded cationic SLN were prepared and extensively characterized *in vitro* with regard to their physicochemical properties, their capacity to load and release PTX, their cytotoxicity and their permeability across hCMEC/D3 cell lines taken as an *in vitro* model of BBB.

2. Experimental

2.1 Chemicals

Sodium Behenate (Na-BA) was purchased from Nu-Chek Prep, Inc. (Elysian, U.S.A.), Tween[®]80, sodium dodecyl sulfate, Triton X-100 and cholesterol from Fluka (Buchs, Switzerland), paclitaxel (PTX) from Indena (Milan, Italy), citric acid from A.C.E.F. (Fiorenzuola d'Arda, Italy), 80% hydrolyzed PVA 9000-10000 Mw (PVA 9000), Pluronic F68, stearylamine (ST), glycol chitosan (GCS), coumarin 6 (Cou-6), triethanolamine phosphate, trehalose, penicilin-streptomycin, hydrocortisone, ascorbic acid, Hepes and b-FGF from Sigma (Dorset, UK), hydrochloric acid, sodium hydroxide and sodium phosphate monobasic from Merck (Darmstadt, Germany), Cremophor® EL from BASF (Ludwigshafen am Rhein, Germany), EBM-2 basal medium from Lonza, (Basel, Switzerland), fetal bovine serum Gold from PAA The Cell Culture Company (Pasching, Austria), rat collagen-I from Trevigen (Gaithersburg, Maryland, USA), chemically defined lipid concentrate from Invitrogen Life technologies (Carlsbad, California, USA), methanol and ethanol from Carlo Erba (Val De Reuil, France). Deionized water was obtained by a MilliQ system (Millipore, Bedford, MO).

2.2 hCMEC/D3 cells

hCMEC/D3 cells, a primary human brain microvascular endothelial cell line that retains the property of BBB *in vitro*, were cultured as reported [38]. Briefly, cells were maintained in Petri dishes coated with 150 μg/ml rat collagen-I and cultured in EBM-2 basal medium supplemented with 5% v/v fetal bovine serum Gold, 1% v/v penicilin-streptomycin, 1.4 μM hydrocortisone, 5 μg/ml ascorbic acid, 10 mM Hepes, 1% v/v Chemically Defined Lipid Concentrate, 1 ng/ml b-FGF. In all the experiments cells were used between passages 29 and 34. For the permeability assays, cells were seeded at 50,000/cm² and grown for 7 days up to confluence in Petri dishes and Transwell devices (0.4 μm diameter pores-size, Corning Life Sciences, Chorges, France), with 1.5

ml/cm² and 3 ml/cm² of the culture medium described above in the Transwell insert and in the lower chamber, respectively.

Before each experiment we measured the transendothelial electrochemical resistance (TEER) and the permeability coefficient of dextran-FITC, [14 C]-sucrose and [14 C]-inulin, taken as parameters of paracellular transport across hCMEC/D3 monolayer, as described in [39]. TEER value was between 30 and 40 Ω x cm², dextran-FITC permeability coefficient was 0.015 \pm 0.003 x 10⁻³ cm/min, [14 C]-sucrose permeability coefficient was 1.19 \pm 0.21 x 10⁻³ cm/min, [14 C]-inulin permeability coefficient was 0.56 \pm 0.09 x 10⁻³ cm/min. These values suggested the functional integrity of BBB monolayer [38].

2.3 GBM cell lines and culture conditions

Primary human GBM cell lines NO3 and CV17 were obtained from primary human GBMs surgically resected at the Department of Neuroscience, Neurosurgical Unit, University of Turin, Italy. The histological diagnosis was performed according to World Health Organization (WHO) guidelines. The study was in compliance with the local institutional review board and Committee on Human Research and with the ethical human-subject standards of the World Medical Association Declaration of Helsinki Research. Written informed consent was obtained from all patients.

010627 GBM cell line was a kind gift of Dr. Galli R, DIBIT San Raffaele, Milan, Italy). For cytotoxicity studies in co-culture models U87-MG cells (ATCC, Rockville, MD) were also used.

By neurosphere assay, from a resected tumor tissue we obtained neurosphere (NS) or adherent cell (AC) or both cell types [40]. NS lines were cultured on Dulbecco's modified Eagle's medium (DMEM)/F-12 supplemented with 20 ng/ml epidermal growth factor (EGF) and 10 ng/ml basic fibroblast growth factor (bFGF); AC lines were grown on DMEM supplemented with 10% fetal bovine serum (FBS) for AC. Both cultures were maintained at 37°C and at 5% O₂/CO₂ in a humidified multigas Sanyo MCO-18M incubator (Sanyo Scientific, Bensenville, IL).

- 222 All cell cultures were periodically checked for *Mycoplasma* contamination (e-MycoTM
- 223 Mycoplasma PCR Detection kit, iNtRON Biotechnology, Korea).

- 2.4 PTX-loaded SLN preparation
- Different SLN formulations were prepared (Table 1); non-charged SLN were prepared as reference
- 227 to evaluate the positive-charge influence.
- Non-charged SLN: SLN were prepared by the coacervation method [35]. Briefly, appropriate
- amounts of Na-BA and PVA 9000 were dispersed in 5 ml deionized water and the mixture was then
- 230 heated under 5 min-stirring (300 rpm) just above the Krafft point of Na-BA (75 °C) to obtain a clear
- solution (micellar solution). A selected acidifying solution (100 µl 1M NaH₂PO₄ + 160 µl 1M HCl)
- was then added drop-wise until pH 4.0 was reached. The obtained BA SLN suspension was then
- cooled in a water bath under 10 min-stirring at 300 rpm until 15 °C temperature was reached. SLN
- suspension was then again heated under stirring (300 rpm) just above the melting point of BA (80
- °C). Different amounts of 30 mg/ml ethanol PTX solution, heated at the same temperature of SLN
- suspension, were added to the warm mixture and then the sample was again cooled in a water bath
- under stirring at 300 rpm until 15 °C was reached.
- 238 Charged SLN: SLN were prepared as described for non-charged SLN, introducing the positive-
- charged agent as follows:
- ST-SLN: a fixed amount of 30 mg/ml 2-propanol ST solution (Table 1) was added to the warm
- aqueous Na-BA solution just above the Krafft point of Na-BA.
- 242 GCS-SLN: an appropriate amount of GCS (Table 1) was added at the beginning of the
- preparation before obtaining the micellar solution.
- All SLN formulations were also prepared in the presence of cholesterol (CHOL-SLN): 100 or 150
- 245 µl of 5 mg/ml ethanol CHOL solution were added to the micellar solution immediately before the
- addition of the acidifying solution.

All SLN formulations were also prepared without drug (unloaded SLN) adding the same amount of

ethanol instead PTX-ethanolic solution.

250

251

252

253

254

255

256

257

258

261

264

265

266

267

268

269

270

271

272

Fluorescent SLN to be employed in *in vitro* experiments were prepared using Cou-6 as fluorescent

lipophilic model drug (Cou-6-CHOL-SLN). 5 ml SLN were prepared in aseptic conditions (under

laminar flow airfilter starting from materials sterilized with UV or in autoclave) adding 100 µl

2mg/ml Cou-6 ethanol solution after SLN fusion. The samples were then cooled in a water bath

under stirring at 300 rpm until 15°C temperature was reached.SLN were lyophilized using a

programmable freeze-dryer (Shin PVTFD10R, Shinil Lab, Korea) without cryoprotectant addition.

Slow freezing was carried out on the shelves in the freeze dryer (shelf temperature -40 °C).

Samples were lyophilized for 24 h from -40 °C to 25 °C at a 5 °C/h. increasing rate. Lyophilized

products were reconstituted by magnetic stirring adding the same water amount.

259 2.5 SLN characterization

SLN shape and mean sizes were characterized by Transmission electron microscope (TEM, CM 10

Philips, The Netherlands) spraying the SLN suspension on the microscope grid by means of an

aerosol-sampling device.

263 Cou-6 localization into SLN dispersion was determined using optical microscopy equipped with a

fluorescent lamp (Leica DM 2500, Solms, Germany) at 1000x magnification.

SLN particle sizes, polydispersity indexes (PDI) and Zeta potential were determined one hour after

preparation using laser light scattering technique-LLS (Brookhaven, New York, USA). Size

measurements were obtained at an angle of 90° at 25 °C using the number method. The dispersions

were diluted with water for size determination or with 0.01 M KCl for Zeta-potential determination,

in order to achieve the prescribed conductibility. Size measurements were also recorded diluting

samples with grown medium used to culture hCMEC/D3 cells to mime the conditions under which

SLN undergo in vitro experiments. For stability studies, the samples were stored at 4°C. All data

were determined in triplicate.

- 273 PTX entrapment efficiency (EE%) was calculated as the ratio between PTX amount in SLN and
- 274 that in the starting micellar solution \times 100. PTX EE% determination was performed as follows: 1
- 275 ml SLN suspension was centrifuged for 15 min at 62,084 g, the precipitate was washed twice with 1
- 276 ml ethanol:water 30:70 to eliminate adsorbed PTX. The solid residue was dissolved in 1 ml ethanol,
- 277 0.5 ml water were then added to precipitate the lipid matrix and the supernatant obtained was
- 278 injected in HPLC for PTX quantification.
- EE% was also determined after 1:100 dilution in different media to mime the dilution that SLN can
- undergo after administration. Briefly, 500 µl SLN were introduced in a 50 ml flask and 49.5 ml
- water or 0.1 M phosphate buffer pH 7.4 or 0.1 M citric acid buffer pH 5.5 were added. The
- suspension was stirred for 2 hours. 8 ml suspension were centrifuged for 15 min at 62,084 g and
- then treated as previously described.
- 285 2.6 HPLC analysis

- 286 HPLC analysis was performed using a LC9 pump (Shimadzu, Tokyo, Japan) with a
- 287 ChromosystemTM ODS 2.5 μ 125×4.6mm column and a C-R5A integrator (Shimadzu, Tokyo,
- Japan); mobile phase: $CH_3CN:H_2O$ 60:40 (flow rate 1ml min⁻¹); detector: $UV \lambda=227$ nm
- 289 (Shimadzu, Tokyo, Japan). Retention time was 2.6 min.
- 290 The limit of quantification, defined as the lowest PTX concentration in the curve that can be
- measured routinely with acceptable precision and accuracy, was 0.013 µmol/ml; the limit of
- 292 determination, defined as the lowest detection limit, was 0.005 μmol/ml (signal to noise>2.0).
- 294 2.7 SLN and PTX stability
- 295 SLN sizes and PTX EE% of samples stored at 4 °C were monitored for 90 days to study SLN
- 296 physical stability and PTX chemical stability. Mean sizes were determined by LLS and PTX EE%
- over time was obtained as described by HPLC.

The same SLN suspensions were freeze-dried without adding any cryoprotectant (FD-SLN) using a Modulyo Freeze Dryer (Edwards Alto Vuoto, Italy). The resulting samples, rehydrated with the same water amount, were also characterized by size, Zeta potential and EE% determination.

2.8 PTX in vitro release

In vitro release of PTX was determined using the non-equilibrium dialysis method [41]. A multicompartmental rotating cell system consisting of donor and receptor compartments of equal volume (1.5 ml) separated by a dialysis membrane (cut-off 12,000 Da) was used. Receiving medium was 0.1 M phosphate buffer (pH 7.4) containing 0.1% v/v Tween®80. Solution of PTX in receiving medium and SLN suspensions were used as donor formulations. At fixed times, the receptor solution was tipped out and used for HPLC analysis and the cell was refilled with fresh receiving medium. Drug concentration was determined by HPLC. The results were evaluated as PTX apparent permeability constant (Kd_{app} [cm h⁻¹]) calculated from the slope of the straight line obtained by plotting the amount of PTX diffused from the donor formulation versus time, assuming pseudo zero-order kinetics.

2.9 Permeability of SLN through hCMEC/D3 cell monolayer

hCMEC/D3 cells, seeded as reported above in Transwell devices, were incubated at day 7 with SLN 2, SLN 9, SLN 15 loaded with Cou-6, for 0.5, 3 and 24 h in the Transwell insert. The amount of SLN added was 100 µl diluted with 900 µl of medium. This dilution of SLN was the highest concentration devoid of cytotoxic effects on hCMEC/D3 cells, as previously reported [42]. In parallel, a set of Transwell inserts were incubated with Cou-6 aqueous suspension obtained with PVA 9000 as suspending agent, containing the same concentration of Cou-6 present in SLN. At the end of the incubation time, the medium in lower chamber was collected, diluted 1: 20 into ethanol, sonicated with 10 bursts of 1 s to disrupt SLN, and centrifuged at 62,084 g for 5 min, to pellet debris. The dilution of the medium was necessary to obtain a fluorescence

falling in the detection range of the LS-5 spectrofluorimeter (PerkinElmer, Waltham, MA), used to measure the fluorescence of Cou-6.

Excitation and emission wavelengths were 485 ± 20 nm and 528 ± 20 nm, respectively. The fluorescence of Cou-6 at t_0 in the upper chamber, was considered 100%. The fluorescence of Cou-6 measured in the medium collected from the lower chamber was expressed as percentage of fluorescence in the upper chamber at t_0 . The fluorescence of the medium without Cou-6 was considered as blank and was subtracted from the fluorescence of all the other experimental conditions.

To measure the amount of Cou-6 adsorbed on the Transwell membrane, Cou-6, either free or loaded in SLN, was added in empty Transwells in the same experimental conditions of the Transwells containing hCMEC/D3 cells, then the medium from the insert and the lower chamber was removed; the Transwell membrane was washed with PBS and 0.5 ml ethanol was added to solubilize the Cou-6 adsorbed on the membrane. The solution was collected and its fluorescence was read as reported above. The fluorescence was always less than 4% of the fluorescence measured in the lower chamber medium in all the experimental conditions, suggesting that such very low absorption of Cou-6 on the Transwell insert did not influence the results of the permeability assays.

The level of significance was determined by a Student's t test. Statistical significance was defined

341 as p < 0.001.

2.10 In vitro cytotoxicity assay

For cytotoxicity studies, NO3 cells (both NS and AC) and CV17 NS were used at various passage numbers between 20 and 30, whereas 010627 cells (both NS and AC) were used at passage numbers between 160 and 180.

Free PTX (Sigma Aldrich Co., St. Louis, MO, USA) was dissolved in 100% DMSO for stock solutions and dilutions for cell treatments were made extemporaneously in culture medium, so that the final concentration of DMSO never exceeded 0.3% (v/v).

- 350 Cell lines were treated for 72 h with increasing doses (20, 100, 500, 1400 nM) of free PTX.
- 351 After exposure the cytotoxic effect of free Paclitaxel (PTX) and PTX-loaded SLN against tumor
- 352 cells was evaluated assessing the number of viable cells by the Trypan blue dye exclusion test,
- using a TC20 automated cell counter (Bio-Rad, Berkeley, CA, USA). As for AC, results were
- 354 confirmed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay
- 355 (Roche, Diagnostic Corporation Indianapolis, IN, USA) [43].
- For Trypan blue assay, cells were plated at a density of 200 x 10³ cells in 5 ml medium in a 25 cm²
- 357 flask and treated with PTX (free in solution or encapsulated in SLN2, SLN9 or SLN15) at 37°C in
- 358 5% O₂/CO₂ for different times (24 and 72 h). Stock solutions were diluted extemporaneously in
- 359 fresh medium at the desired concentration and administered to cells.
- 360 Cytotoxicity was expressed as number of surviving cells as percentage of control (untreated cells).
- For MTT assay, cells were seeded in 96-well plates (1 x 10⁴ cells/well in 100 µl medium) and
- 362 treated with the different concentrations and times above indicated of the drug (free or
- encapsulated) at 37 °C in 5% O₂/CO₂. The medium with the SLN was replaced with fresh medium
- and 10 µl of MTT solution (5mg/ml) were added to each well and incubated for 4 h at 37 °C. The
- extent of cell viability is indicated by mithocondrial conversion of yellow MTT, a tetrazole, to
- purple formazan by the living cells. Formazan crystals were solubilized overnight in 10% sodium
- dodecyl sulfate (SDS), 0.01 M HCl and optical density was measured at 570 nm (test wavelength)
- and 660 nm (reference wavelength) using a microplate spectrophotometer (Synergy HT, BioTek
- 369 Instruments Inc., Winooski, VT, USA). Cell viability was expressed as a percentage of the
- absorbance measured in the treated cells compared to the control (untreated cells). All experiments
- were performed in quadruplicate.
- 372 The concentration of free PTX which caused a 50% cell growth inhibition (IC₅₀) compared with
- untreated controls, was calculated by non-linear regression for each cell line.
- To investigate the cytotoxic effect of PTX incorporated in SLN, a drug concentration of 100 nM
- was chosen for the following *in vitro* experiments.

- 376 Cell viability was also measured after treatment with unloaded SLN (SLN2, SLN9 and SLN15) at
- the highest SLN concentration used for the study, *i.e.* 0.1% w/v.
- 378 The level of significance was determined by a two-tailed Student's t test. Statistical significance
- 379 was defined as p < 0.05 or p < 0.01.

- 381 2.11 DNA damage/repair study by Immunofluorescence (IF)
- The occurrence of a DNA damage after SLN treatment was investigated through the analysis by IF
- of γ -H2AX histone, that localizes at sites of DNA fragmentation as subnuclear foci.
- The cell response to DNA insults was studied monitoring the activation of p-ATM, p-Chk2 and p-
- 53BP1. HR or NHEJ repair system activities were analyzed through RAD51 or Ku70/Ku80 and
- 386 DNA-PKcs proteins respectively. After 72 h treatment with unloaded SLN (SLN9) or with 100 nM
- 387 PTX-loaded SLN9, cells were fixed for 20 minutes with 4% paraformaldehyde at room
- temperature, rinsed three times with PBS, blocked/permeabilized with PBS containing 2% of the
- appropriate serum and 0.1% Triton X-100 for 30 minutes and stained with the following primary
- antibodies: mouse anti-γ-H2AX (Ser139), mouse anti-p-ATM (Ser1981) (both from Millipore),
- rabbit anti-p-Chk2 (Thr68) (Cell Signaling Technology), rabbit anti-p-53BP1 (Ser25) (Bethyl
- Laboratories), mouse anti-RAD51, mouse anti-DNA-PKcs and mouse anti-Ku70/Ku80 (all from
- NeoMarkers). Negative controls were obtained by omitting the primary antibody. Alexa Fluor®
- 394 488-AffiniPure goat anti-rabbit IgG and Alexa Fuor® 594-AffiniPure rabbit anti-mouse IgG
- 395 (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) were used as secondary
- antibodies. Cell nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI) and
- observations were made under a Zeiss Axioskop fluorescence microscope (Karl Zeiss, Oberkochen,
- 398 Germany) equipped with an AxioCam5MR5c and coupled to an Imaging system (AxioVision
- Release 4.5; Karl Zeiss).

400

Analysis by TEM was employed in order to get information on the possible ultrastructural 402 modifications of cells treated with empty and PTX-loaded SLN. NO3 NS and AC lines were used 403 for the investigation. 404 For transmission electron microscopy, untreated cells, cells treated with unloaded SLN15 and cells 405 treated with 100 nM PTX-loaded SLN15 for 24 h were collected, pelleted by centrifugation and 406 then fixed with 2.5% glutaraldehyde prepared in 0.1 M phosphate buffer at 4 °C. Samples were 407 post-fixed with 1% osmium tetroxide for 2 h, dehydrated in a graded acetone series and embedded 408 in the Epon 812 epoxy resin. Ultrathin sections were prepared using an ultracut microtome 409 (Reichert-Jung, Germany), collected on copper grids, stained with both lead citrate and uranyl 410 411 acetate, and then observed with a Philips CM-12 transmission electron microscope.

412

413

414

2.13 Glioblastoma cell cytotoxicity in co-culture models

human glioblastoma cells CV17 and 01010627) were added in the lower chamber of Transwells 4 415 416 days after seeding hCMEC/D3 cells in the upper chamber of Transwells. After 3 days of co-culture the medium of the upper chamber was replaced with fresh medium, with or without free PTX or 417 PTX-loaded SLN (SLN 2) at different concentration (20, 50, 100, 200, 500 nM) for 24 h, as 418 detailed under results. 419 To measure the viability of glioblastoma cells co-cultured with hCMEC/D3 cells, extracellular 420 medium of glioblastoma cells was collected and centrifuged at 12,000 g for 15 min to pellet cellular 421 debris, whereas cells were washed with fresh medium, detached with trypsin/EDTA (0.05/0.02% 422 v/v), re-suspended in 0.2 ml of 82.3 mmol/l triethanolamine phosphate-HCl (pH 7.6) and sonicated 423 on ice with two 10 s bursts (Labsonic sonicator, 100 W). LDH activity was measured in the 424 425 extracellular medium and in the cell lysate: 50 µl of supernatant from extracellular medium or 5 µl of cell lysate were incubated at 37 °C with 5 mmol/l NADH. The reaction was started by adding 20 426 mmol/l pyruvic acid and was followed for 6 min, measuring absorbance at 340 nm with Packard 427

In co-culture experiments, 500,000 glioblastoma cells (i.e. the U87-MG cell line and the primary

428 EL340 microplate reader (Bio-Tek Instruments, Winooski, VT). The reaction kinetics was linear

throughout the time of measurement. Both intracellular and extracellular enzyme activity was

expressed in µmol NADH oxidized/min/dish, then extracellular LDH activity was calculated as

percentage of the total LDH activity in the dish.

429

430

432

433

The level of significance was determined by a Student's t test. Statistical significance was defined

as p < 0.05, p < 0.02, p < 0.01, p < 0.005 or p < 0.001.

3. Results and discussion

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

As described in the introduction chapter, BBB is a physical barrier characterized by tight intracellular junctions and by the absence of fenestrations that limit permeability for therapeutic molecules with no exception for molecules in the glioblastoma treatment. The use of drug-loaded nanoparticles could be a winning strategy if an active targeting and a suitable drug concentration to the brain could be obtained, provided small-sized hydrophilic vehicles are achieved to prevent rapid degradation by reticuloendothelial system and carriers with proper superficial characteristics are coupled. Moving from this background, SLN were prepared using the coacervation method which uses hydrophilic polymeric as stabilizers able to confer hydrophilic surface to SLN. Further to a cytotoxicity study against hCMEC/D3 cells relating to different fatty acids [40], BA was chosen as lipid matrix. In order to take advantages of possible interaction between BBB negative charges and surface positive-charged SLN, two positive charged molecules currently used in literature were introduced in the SLN preparation: ST [44] and GCS [36]. As antineoplastic model drug PTX was chosen, a lipophilic molecule suitable to be entrapped in SLN matrix. Preliminary formulation studies (data not reported) demonstrated the need to modify the preparation procedure to obtain higher drug EE% by introducing PTX after SLN melting instead of adding it to the micellar solution; probably the high PTX lipophilicity does not allow its distribution within micelles, while promoting its solubilization in the molten lipid.

453

454

452

3.1 SLN characterization

- In Table 1 compositions of PTX-loaded SLN are reported. SLN composition was the result of a
- preliminary screening carried out in a previous work [45].
- 457 In Table 1 ST-SLN and GCS-SLN compositions are also reported. Different formulations were
- obtained varying the amount of PVA 9000, ST, GCS or PTX in order to obtain the most suitable
- 459 PTX vehicle as concerns Zeta potential, mean sizes, EE%, over time stability. In order to improve

SLN stability, CHOL was also added. As reported in literature [46] high CHOL/lipid ratio matrix reduced mean diameters of SLN prepared from emulsion. This led to a rigid surfactant layer with decrement in van der Waals attraction and promotion of net repulsion forces between oil droplets; therefore, agglomeration and coalescence of small oil droplets were reduced. In addition, the interaction between CHOL and surface active agent might increase the surface curvature of oil droplets consequently leading to small size of SLN after cooling down. A similar behavior can be hypothesized also in SLN obtained by coacervation. In the present experimental conditions, CHOL probably might interact with Na-BA at the interface of micelles. In Table 1 SLN, ST-SLN and GCS-SLN mean diameter and Zeta potential are reported. Most SLN tested had sizes below 600 nm. In the neutral SLN series (SLN 0-3), increasing the amount of PTX no changes in particles dimension were noted; different behavior was noted in the case of charged SLN. In the ST-SLN series (SLN 4-10) an increase in diameter sizes can be noted when ST or PTX amounts were increased or when CHOL was introduced in the formulation. Nevertheless the presence of CHOL was essential to SLN stability: in the absence of CHOL, ST-SLN and GCS-SLN showed a sudden increase in mean size immediately after preparation. Instead, in the GCS-SLN (SLN 11-17) series a slightly decrease in SLN size was obtained increasing the GCS amount and a more marked increase was noted when a great amount of stabilizer (PVA) was used. Also in this case the presence of CHOL was necessary to formulations stability; the addition of this component led to a decrease in mean diameter and the smallest SLN were obtained using 50 mg (1% w/w) PVA (SLN 17). The dissimilar influence of ST and GCS on ST-SLN and GCS-SLN sizes might be due to different positioning of both charged molecules: probably, lipophilic ST chain was incorporated in the lipid matrix while GCS was mainly adsorbed to the external surface of nanoparticles. Size measurements were employed also diluting the samples with growth medium used in the in vitro experiments in order to verify SLN sizes when they are tested in vitro. The growth medium does not seem to influence SLN dimensions: all SLN have maintained their size (data not reported).

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

In Figures 1a and 1b TEM PTX-SLN2 images at different magnifications were reported. The SLN 486 have spherical shape and sizes between 300 and 500 nm. The drug introduction does not seem to 487 affect shape and size (data not reported). Similar characteristics were obtained also with SLN9 and 488 489 SLN15. The observation of Cou-6-SLN nanosuspensions under optical microscope confirmed both the 490 spherical shape and the dimensional range of the particles. The use of fluorescent light allowed to 491 locate Cou-6 in SLN nanosuspensions: homogeneous dispersions of fluorescent nanoparticles were 492 493 observed with all formulations (data not shown). In Table 1 also Zeta potential values are reported. All GC or ST-containing formulations showed 494 positive charge with values in the 7.6 - 23.8 mV range. ST-SLN presented Zeta potential ranging 495 from 7 to 15 mV (depending on ST amount used); these values are smaller than those of GCS-SLN 496 and those of SLN containing the same ST percentages but prepared with methods other than 497 498 coacervation [41]; probably PVA 9000 used as stabilizer locates itself externally thus partially 499 screening the ST positive charge. 500 In GCS-SLN series, Zeta potential values confirmed the external positioning of the polymer: probably positively-charged GCS interacted with carboxylate groups on SLN surface, conferring 501 them a positive charge. The values were influenced by GCS amount: by increasing the polymer an 502 increase of Zeta potential from 16.9 mV to 23.8 mV was noted; the presence of CHOL and the PTX 503 504 amount variation did not seem to influence this parameter. In Table 2 the amount of PTX in SLN is expressed as EE% and as loading (mg PTX/mg BA). 505 Almost all tested SLN showed a good PTX loading capacity; in particular, in neutral SLN series 506 (SLN 0-3) PTX EE% did not significantly vary increasing the drug amount, while drug loading was 507 increased over twice folds. In the ST-SLN series (SLN 4-10), PTX EE% was significantly 508 509 influenced by several factors. Increasing ST amounts determined a reduction of PTX EE% (SLN 5) which was partially counteracted by the presence of CHOL (SLN 6) probably as a consequence of a 510

511 hardened structure of SLN surface. Also PVA amount seemed to be relevant in influencing PTX

EE%, as higher PVA concentrations determined a reduction in PTX EE%.

In GCS-SLN series (SLN 11-17), EE% and PTX loading ranged from 24% to 83% and from 1.4 to

5.0 mg/mg BA respectively. Also in this series PTX EE% was strongly influenced by PVA 9000

amount: when the highest stabilizer amount was used (SLN 14), a dramatic decrease in drug EE%

up to 24% can be noted; probably PVA 9000 formed micelles in aqueous phase able to solubilize

PTX. CHOL introduction enhanced PTX EE% from 52% to 75% particularly in SLN prepared with

50 mg PVA 9000. On the contrary, GCS amount variations did not seem to affect drug EE%.

To mime SLN behavior after administration when they are diluted in physiological fluids, drug

EE% was determined also after 1:100 dilutions. When water was used as dilution medium, EE%

remained almost unvaried in all ST-SLN (±1%), except in SLN 15 in which a 10% decrease was

registered. Probably, in GCS-SLN, PTX is partially trapped in GCS chains located on SLN surface

and therefore it might be released upon high dilutions. To evaluate the influence of different

dilution media, SLN 9, which were chosen as those having the best properties for our experimental

purposes, were diluted also by pH 7.4 PBS and pH 5.5 citric buffer. No significant variation was

noted upon dilution by pH 7.4 PBS (±1%), while a certain PTX amount was released when 0.1

citric pH 5.5 buffer was used, that mimed the lysosomial environment: the EE% decreased from

92% to 77% and this could be due to a PTX slow release.

529

530

531

532

533

534

535

536

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

3.2 SLN and PTX stability

The studies were carried out only on SLN giving the best results concerning sizes and EE%. The

chosen formulations were analyzed to verify their stability overtime. The results are reported in

Table 3. SLN 9 showed a great increase in mean diameter (up to 1500 nm) after 30 days, while only

a slight decrease occurred in EE%. The poor dimensional stability of SLN 9 could be due to their

low Zeta potential (about 9 mV) which is probably not sufficient to prevent SLN aggregation. On

the other hand, GCS-SLN (SLN 15, 16, 17) showed a higher dimensional stability although a

gradual increase in mean diameter and a gradual decrease in Zeta potential were registered due probably to a slow solubilization of the external GCS coating in the aqueous phase. To overcome the poor stability of SLN suspension and to find an optimal storage method, they were submitted to freeze drying. In Table 4 SLN sizes after freeze-drying were reported. The freeze-

drying process was carried out without adding any cryoprotectant; in fact in a previous work [45]

PVA 9000 was found to be able to protect SLN during freeze-drying as well as 2% threalose.

The characterization of resulting SLN suspensions showed a mean diameter increase of all SLN analyzed probably due to a partial SLN aggregation. This increase was about 300 nm in SLN with ST while only a slight variation was registered in SLN with GCS; probably also GCS, positioning externally, could behave as cryoprotectant preventing nanoparticles aggregation. The smallest increase (about 40 nm) was noted when higher amounts of stabilizer were used. EE% was kept constant in almost all preparations; an increase in EE% (from 75% up to 89%) was registered in SLN 17 that presented a higher amount of free PTX: probably during freeze-drying a part of free PTX was internalized or absorbed onto nanoparticles.

3.3 Determination of PTX release

In Figure 2 PTX release plots from SLN using the dialysis method were reported. In this experiment drug diffusion through the dialysis membrane was influenced by drug release rate from SLN. As it can be seen, PTX was released very slowly from SLN: less than 1% PTX was released from SLN formulations in 12 hours while, at the same time, about 40% PTX diffused from PTX solution. This slow release could confirm PTX incorporation into SLN. From the $K_{d\ app}$ data it could be seen as PTX release from GCS-SLN was still slower than from ST-GCS; these results could be the confirmation that GCS formed an external coating that further limited drug release.

3.4 Permeability of SLN across BBB

As shown in Figure 3, the permeability of free Cou-6 across the hCMEC/D3 monolayer remained very low at all the time points considered; the permeability of Cou-6-loaded SLN was similar to that of free Cou-6 after 0,5 h, but became significantly higher after 3 h and 24 h. Apparently there were no differences in the permeability of uncharged SLN (SLN 2) versus positively charged SLN (SLN 9 and SLN 15), although SLN 9 resulted the best permeable formulation after 24 h.

568

- 3.5 In vitro cytotoxicity studies
- To assess the sensitivity of the five malignant glioma cell lines to PTX, we treated previously the
- 571 cells with Cremophor® EL:ethanol 50:50 drug solution (free PTX) at concentrations ranging from
- 572 20 nM to 1.4 μM for 72 h.
- After different exposure times both MTT and trypan blue assays were performed. PTX was able to
- block in vitro cellular proliferation in a dose-dependent manner; it inhibited clonogenic growth of
- NS (Figure 4a–4d) and hindered adhesion process in AC (Figure 4e–4i).
- 576 The growth inhibitory effect was more evident on AC than on NS.
- 577 The IC₅₀ values of free PTX at 72 h for the three NS cell lines studied were < 20 nM; for the two
- AC lines were < 15 nM (Figure 5). Consequently, drug concentration of 100 nM was employed for
- 579 the following experiments with PTX incorporated in SLN. At this dosage, a statistically significant
- decrease of cell viability was caused by PTX compared with untreated cells, both as free drug and
- as SLN-carried, and this effect increased prolonging drug exposure time from 24 to 72 h. It was
- observed that also PTX encapsulated in SLN caused inhibition of sphere formation in the NS
- cultures (Figure 4e) and interfered with cell adhesion in AC cultures (Figure 4l).
- Graphs in Figure 7 show cell viability of NO3 line after the treatments: as regards NS, the viable
- cell number decreased to 60-70% after 24 h treatment with the different PTX-SLN (Figure 6a) and
- to 30-40% after 72 h treatment (Figure 6b). At 24 h free PTX and all PTX-SLN gave a cytotoxicity
- statistically different from control, while only SLN 2 produced an increase in cytotoxicity

significantly different from that of empty SLN 2. Prolonging the incubation time, also SLN 9 were 588 significantly different from the corresponding empty SLN. 589 The reduction of viability of AC was about 10-15% higher than the one of NS (Figure 7). An 590 analogous behavior of PTX-SLN 2 and PTX-SLN 9 was noted already after 24 h incubation, while 591 after 72 h all SLN under study produced a cytotoxicities significantly different from those produced 592 by the corresponding empty SLN. The cytotoxicity of PTX incorporated in SLN appeared similar 593 or even slightly higher in comparison with the one of free drug solution. In particular, SLN2 seemed 594 595 to enhance growth inhibitory activity of PTX on NS lines, while SLN 9 did it on AC lines. The results slightly varied in the other cell lines (data not shown), but the cytotoxic activity of PTX-596 loaded SLN remained always equal or greater compared with free drug. SLN 2 and SLN 9 appeared 597 as the most effective carrier formulations. 598 Control experiments demonstrated that the exposure of the cells with the unloaded SLN at the 599 600 highest SLN concentration used for the study determined a mild reduction of cell viability too, mostly on AC. Unloaded SLN 2 formulation displayed the smallest cytotoxic effect, while unloaded 601 602 SLN15 had a more accentuated action on cell proliferation. 603 Treatment with PTX vehicle (50:50 v/v mixture of Cremophor® EL and ethanol) at the same concentrations used for drug solutions showed a slight cytotoxicity too (data not reported). 604 Our results suggest that, first of all, incorporation of PTX in SLN did not alter its cytotoxic 605 capability and that these carriers, thanks to a good cell membrane permeation, are able to efficiently 606 transport the drug inside the cells. Encapsulation into SLN appeared even to enhance the growth 607 inhibitory effect of PTX on GBM cell lines. 608 609 In conclusion, loading of PTX in SLN seems to sensitize cells and to decrease their resistance to the

611

612

610

drug.

3.6 Study of PTX-SLN cytotoxic effect by TEM

The observation by TEM enabled to evaluate the ultrastructural alterations of cells after exposure to SLN. The analysis revealed that the administration of unloaded SLN 15 didn't cause modifications to the cell morphology both in NS and in AC. Cells treated with empty SLN maintained unchanged nucleus, ergastoplasma, Golgi apparatus and mithocondria (Figure 8a).

On the contrary, 24 h exposure to SLN loaded with 100 nM PTX induced severe alterations of the cellular morphology that included cytoplasmic accumulation of vacuoles, loss of mitochondrial ridges and finally mithocondrial lysis (Figure 8b-8f). The vacuoles became gradually larger and confluent and in some cases they blended and formed autophagolysosomes surrounded by a membrane. Cytoplasmic rarefaction, glycogen accumulation and destruction of all organelles suggested a typical regressive apoptotic pattern. Only in some areas there was evidence of SLN

residues. These results indicate an evident cell damage caused by the PTX vehicled in the SLN.

3.7 DNA damage and repair response induced by PTX-SLN treatment

In response to DNA damage caused by genotoxic agents, the eukaryotic cell activates a complex checkpoint/repair pathway in order to repair the lesion before replication. The signalling involves the recruitment of the sensor protein kinase ataxia telangiectasia mutated (ATM), that initiates a transduction cascade phosphorylating downstream effectors, including H2AX histone, 53 binding protein 1 (53BP1) and the checkpoint kinases 1 and 2 (Chk1 and Chk2). When checkpoints are activated, the cell cycle is halted to allow DNA repair. If the damage is too severe, repair fails and the cell enters into apoptosis [47]. Two are the major pathways used by mammalian cells to repair double strand break damage: the homologous recombination (HR), which takes place during the S and G2 phases and is driven mainly by RAD51 protein, and the non-homologous end joining (NHEJ), which occurs during G0 and G1 phases. The key NHEJ effector is DNA-dependent protein kinase (DNA-PK), which consists of a regulatory subunit (Ku70/Ku80 heterodimer) and a catalytic subunit (DNA-PKcs) [48]. In glioma cells, increased DNA damage response and repair ability contribute to determine the radio- and chemoresistant phenotype of these cells [49].

After glioma cell treatment for 72 h with relatively high concentration (100 nM) of free PTX we 639 640 observed a moderate activation of checkpoint and repair proteins. A mild expression of all markers, was found both in NS and in AC (data not shown), indicating that this drug is able to induce 641 genotoxic lesions. 642 Even after NO3 cell line treatment with PTX carried by SLN, we found the presence of γ -H2AX 643 positive-nuclei and a moderate expression of all sensors and effectors of checkpoint/repair pathway, 644 645 both in NS (Figure 9a-9g) and in AC (Figure 9l-9q), demonstrating that the encapsulated drug maintains the ability to induce a DNA strand break damage in the glioma cell lines. As already 646 647 observed for the free drug, mostly on AC lines, several cells treated with PTX-SLN appeared blocked in metaphasis (Figure 9i) and presenting a strong expression of the checkpoint/repair 648 649 proteins (p-ATM, p-Chk2, p-53BP1, γ-H2AX, DNA-PKcs). It seemed from these findings that cells try to repair the genotoxic lesions mainly through the NHEJ system. Untreated cells were negative 650 651 for all markers (inserts in Figure 9a and 9i are examples for p-ATM expression). After exposure of cells to unloaded SLN for 72 h we did not observe positivity of any 652 checkpoint/repair protein (panels h and r of Figure 9 are examples for p-ATM expression). 653

654

655

656

657

658

659

660

661

662

663

664

3.8 Effective cytotoxicity of paclitaxel-loaded SLN against glioblastoma cells in co-culture models. The cytotoxicity of PTX-loaded SLN on glioblastoma cells was finally compared with that of free PTX in co-culture models of hCMEC/D3 cells and glioblastoma cells. As shown in Figures 10, 11 and 12, free PTX induced a dose-dependent increase of cytotoxicity in all the glioblastoma cell lines; PTX-loaded SLN followed a similar trend and showed – at the same concentration – higher efficacy than the free drug. Also the toxicity on hCMEC/D3 cells increased dose-dependently, without significant differences between free PTX and PTX-loaded SLN (Figure 13).

By comparing the cytotoxicity profile on glioblastoma cells and hCMEC/D3 cells, we can state that

PTX-loaded SLN achieves significant toxicity against tumor cells at concentrations that are not

toxic for BBB cells. To obtain the same degree of cytotoxicity on glioblastoma cells, free PTX

should be used at concentration that are unacceptably toxic for brain microvascular endothelial cells. The different efficacy of free versus SLN-loaded PTX can be explained by the increased permeability of the latter through the BBB monolayer. PTX is a known substrate of P-glycoprotein (Pgp) [50], which is abundant on the luminal side of BBB cells [51]; therefore, it is a poorly delivered drug into the brain parenchima. Its loading within SLN may represent a valid strategy to overcome the efflux by Pgp at BBB levels.

In addition, also glioblastoma has been reported to be rich of Pgp [52] and multidrug resistance related protein 1 (MRP1) [53], a second protein that actively effluxes PTX [50], limiting its intracellular accumulation and toxicity. Therefore, a lower accumulation and toxicity of paclitaxel is expected within glioblastoma cells. The loading within SLN may promote a faster uptake and/or a lower efflux by Pgp and MRP1 from glioblastoma cells as well. Therefore, the loading in SLN may represent a valid strategy to simultaneously bypass the drug efflux at BBB and glioblastoma levels.

4. Conclusion 677 The fatty acid coacervation technique, a solvent free method, was used to prepare PTX-loaded SLN. 678 The use of positive-charged molecules, such as ST and GCS, allowed to obtain positive SLN with 679 sizes in the 300-600 nm range and PTX EE% in the 25-90% range. 680 Permeability studies through hCMEC/D3 cells monolayer, assumed as in vitro model of the BBB, 681 showed a significantly increase in the permeation of Cou-6, used as model drug, when vehicled in 682 SLN; no significantly differences in the permeability of uncharged SLN versus positively charged 683 SLN were noted after 24 h. 684 Cytotoxicity studies on NO3 glioblastoma cell line demonstrated the absence of toxicity of 685 unloaded SLN 2 and 9 and the preservation of cytotoxic activity of PTX-loaded SLN that remained 686 always equal or greater compared with free drug. 687 In co-culture experiments with hCMEC/D3 and different glioblastoma cells, it was demonstrated 688 689 that, when delivered in SLN, PTX increased its cytotoxicity towards glioblastoma cells, because of its increased permeation through the endothelial cell monolayer. 690 691 According to these *in vitro* results, the positive charge did not seem essential to enhance PTX brain 692 uptake but fundamental seem to be the PTX encapsulation into SLN. Further i.v. administration of PTX-loaded SLN in rats are in progress to confirm the suitability of 693 SLN in enhancing PTX overcoming of the BBB. 694 695 696

Acknowledgements

697

698

699

The authors wish to acknowledge Compagnia di San Paolo, under the research project "Development of solid lipid nanoparticles (SLN) as vehicles of antineoplastic drugs to improve the pharmacological glioblastoma therapy" (ORTO11WINST).

700 References

- 701 [1] M.K. Nicholas, R.V. Lukas, S. Chmura, B. Yamini, M. Lesniak, P. Pytel, Molecular
- heterogeneity in glioblastoma: therapeutic opportunities and challenges, Semin. Oncol. 38 (2011)
- 703 243–253.
- 704 [2] M. Weller, Novel diagnostic and therapeutic approaches to malignant glioma, Swiss Med. Wkly.
- 705 141 (2011) doi:10.4414/smw.2011.13210
- 706 [3] W. Loscher, H. Potschka, Drug resistance in brain diseases and the role of drug efflux
- 707 transporters, Nat. Rev. Neurosci., 6 (2005), 591-602.
- 708 [4] B.T. Hawkins, T.P. Davis, The blood-brain barrier/neurovascular unit in health and disease,
- 709 Pharmacol. Rev. 57 (2005), 173-185.
- 710 [5] N.R. Saunders, C.J. Ek, M.D. Habgood, K.M. Dziegielewska, Barriers in the brain: a
- 711 renaissance?, Trends Neurosci. 31 (2008), 279-286.
- 712 [6] M.L. Pinzón-Daza, I. Campia, J. Kopecka, R. Garzón, D. Ghigo, C. Riganti. Nanoparticle- and
- 713 liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain
- 714 barrier, Curr. Drug Metab. 14 (2013), 625-640.
- 715 [7] M.W. Brightman, T.S. Reese, Junctions between intimately apposed cell membranes in the
- 716 vertebrate brain, J. Cell. Biol. 40 (1969) 648–677.
- 717 [8] A. Béduneau, P. Saulnier, J. Benoit, Active targeting of brain tumors using nanocarriers,
- 718 Biomaterials 28 (2007) 4947–4967.
- 719 [9] M.S. Lesniak, U. Upadhyay, R. Goodwin, B. Tyler, H. Brem, Local delivery of doxorubicin for
- the treatment of malignant brain tumors in rats, Anticancer Res. 25 (2005) 3825–3831.
- 721 [10] T.F. Cloughesy, K.L. Black, Pharmacological blood-brain barrier modification for selective
- 722 drug delivery, J. Neuro-Oncol. 26 (1995) 125–132.
- 723 [11] A.A. Sinkula, S.H. Yalkowsky, Rationale for design of biologically reversible drug
- 724 derivatives: prodrugs, J. Pharm. Sci. 64 (1975) 181–210.

- 725 [12] E. Garcia-Garcia, K. Andrieux, S. Gil, P. Couvreur, Colloidal carriers and blood-brain barrier
- 726 (BBB) translocation: A way to deliver drugs to the brain? Int. J. Pharm. 298 (2005) 274–292.
- 727 [13] M.I. Alam, S. Beg, A. Samad, S. Baboota, K. Kohli, J. Ali, A. Ahuja, M. Akbar, Strategy for
- effective brain drug delivery, Eur. J. Pharm. Sci. 40 (2010) 385–403.
- 729 [14] J. Kreuter, Nanoparticulate systems for brain delivery of drugs, Adv Drug Deliver Rev 47,
- 730 (2001) 65-81.
- 731 [15] P.R. Lockman, J.M. Koziara, R.J. Mumper, D.D. Allen, Nanoparticle surface charges alter
- blood-brain barrier integrity and permeability, J. Drug Target. 12 (2004) 635–641.
- 733 [16] K. Park, Transport across the blood-brain barrier using albumin nanoparticles, J. Control.
- 734 Release 137 (2009) 1.
- 735 [17] A. Mistrya, S. Stolnika, L. Illum, Nanoparticles for direct nose-to-brain delivery of drugs, Int.
- 736 J. Pharm. 379 (2009) 146–157.
- 737 [18] J. Kreuter, P. Ramge, V. Petrov, S. Hamm, S.E. Gelperina, B. Engelhardt, R. Alyautdin, H.
- Von Briesen, D.J. Begley, Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate)
- nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to
- 740 the nanoparticles, Pharm. Res. 20 (2003) 409–416.
- 741 [19] A.E. Gulyaev, S.E. Gelperina, I.N. Skidan, A.S. Antropov, G.Y. Kivman, J. Kreuter,
- Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles, Pharm.
- 743 Res. 16 (1999) 1564–1569.
- 744 [20] J. Kreuter, R.N. Alyautdin, D.A. Kharkevich, A.A. Ivanov, Passage of peptides through the
- blood-brain barrier with colloidal polymer particles (nanoparticles), Brain Res. 674 (1995) 171-
- 746 174.
- 747 [21] S.S. Feng, L. Mu, K.Y. Win, G. Huang, Nanoparticles of biodegradable polymers for clinical
- administration of paclitaxel, Curr. Med. Chem. 11 (2004), 413–424.

- 749 [22] J.M. Koziara, P.R. Lockman, D.D. Allen, R.J. Mumper, Paclitaxel nanoparticles for the
- potential treatment of brain tumors, J. Control. Release 99 (2004) 259–269.
- 751 [23] J.F. Poduslo, G.L. Curran, Polyamine modification increases the permeability of proteins at the
- blood-nerve and blood-brain barriers, J. Neurochem. 66 (1996) 1599–1609.
- 753 [24] Z. Nagy, H. Peters, I. Huttner, Charge-related alterations of the cerebral endothelium, Lab.
- 754 Invest. 49 (1983) 662–671.
- 755 [25] J.E. Hardebo, J. Kahrstrom, Endothelial negative surface charge areas and blood-brain barrier
- 756 function, Acta Physiol. Scand. 125 (1985) 495–499.
- 757 [26] L. Fenart, A. Casanova, B. Dehouck, C. Duhem, S. Slupek, R. Cecchelli, D. Betbeder,
- 758 Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in
- vitro model of the blood-brain barrier, J. Pharmacol. Exp. Ther. 291 (1999) 1017–1022.
- 760 [27] W. Lu, Y. Zhang, Y. Tan, K. Hu, X. Jiang, S. Fu, Cationic albumin-conjugated pegylated
- nanoparticles as novel drug carrier for brain delivery, J. Control. Release 107 (2005) 428–448.
- 762 [28] P. Blasi, A. Schoubben, G. Traina, G. Manfroni, L. Barberini, P.F. Alberti, C. Cirotto, M.
- Ricci, Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity, Int. J.
- 764 Pharm. 454 (2013) 316–323.
- 765 [29] M. Patel, E.B. Souto, K.K. Singh, Advances in brain drug targeting and delivery: limitations
- and challenges of solid lipid nanoparticles, Expert Opin. Drug Deliv. 10 (2013) 889-905.
- 767 [30] M.J. Glantz, M.C. Chamberlain, S.M. Chang, M.D. Prados, B.F. Cole, The role of paclitaxel in
- the treatment of primary and metastatic brain tumors, Semin. Radiat. Oncol. 9 (1999) 27–33.
- 769 [31] S.H. Tseng, M.S. Bobola, M.S. Berger, J.R. Silber, Characterization of paclitaxel (Taxol)
- sensitivity in human glioma- and medulloblastoma-derived cell lines, Neuro-Oncology 1 (1999)
- 771 101–108.

- 772 [32] A. Desai, T. Vyas, M. Amiji, Cytotoxicity and apoptosis enhancement in brain tumor cells
- upon coadministration of paclitaxel and ceramide in nanoemulsion formulations, J. Pharm. Sci. 97
- 774 (2008) 2745–2756.
- 775 [33] S. Fellner, B. Bauer, D.S. Miller, M. Schaffrik, M. Fankhaenel, T. Spruh, G. Bernhardt, C.
- Graeff, L. Faerber, H. Gschaidmeier, A. Buschsuer, G. Fricker, Transport of Paclitaxel (Taxol)
- across the blood–brain barrier in vitro and in vivo, J. Clin. Invest. 10 (2002) 1309–1317.
- 778 [34] P. Ma, R.J. Mumper, Paclitaxel Nano-Delivery Systems: A Comprehensive Review, J
- 779 Nanomed Nanotechol 4 (2013) doi:10.4172/2157-7439.1000164
- 780 [35] L. Battaglia, M. Gallarate, R. Cavalli, M. Trotta, Solid lipid nanoparticles produced through a
- 781 coacervation method, J. Microencapsul. 27 (2010) 78–85.
- 782 [36] A. Trapani, J. Sitterberg, U. Bakowsky, T. Kissel, The potential of glycol chitosan
- nanoparticles as carrier for low water soluble drugs, Int. J. Pharm. 375 (2009) 97–106.
- 784 [37] S. Mao, W. Sun, T. Kissel, Chitosan-based formulations for delivery of si-RNA and DNA
- systems for protein therapeutics and antigens, Adv. Drug Del. Rev. 62 (2010) 12–27.
- 786 [38] B.B. Weksler, E.A. Subileau, N. Perrière, P. Charneau, K. Holloway, M. Leveque, H. Tricoire-
- 787 Leignel, A. Nicotra, S. Bourdoulous, P. Turowski, D.K. Male, F. Roux, J. Greenwood, I.A.
- Romero, P.O. Couraud, Blood-brain barrier-specific properties of a human adult brain endothelial
- 789 cell line, Faseb. J. 19 (2005) 1872-1874.
- 790 [39] C. Riganti, I.C. Salaroglio, M.L. Pinzòn-Daza, V. Caldera, I. Campia, J. Kopecka, M. Mellai,
- 791 L. Annovazzi, P.O. Couraud, A. Bosia, D. Ghigo, D. Schiffer, Temozolomide down-regulates P-
- 792 glycoprotein in human blood-brain barrier cells by disrupting Wnt3-signalling, Cell Mol Life Sci
- 793 71 (2014) 499-516.
- 794 [40] V. Caldera, M. Mellai, L. Annovazzi, A. Piazzi, M. Lanotte, P. Cassoni, D. Schiffer, Antigenic
- and Genotypic Similarity between Primary Glioblastomas and Their Derived Neurospheres, J.
- 796 Oncol. ID 314962 (2011) doi:10.1155/2011/314962.

- 797 [41] M. Trotta', E. Peira, M.E. Carlotti, M. Gallarate, Deformable liposomes for dermal
- administration of methotrexate, Int. J. Pharm. 270, (2004) 119-125.
- 799 [42] L. Battaglia, M. Gallarate, E. Peira, D. Chirio, E. Muntoni, E. Biasibetti, M.T. Capucchio, A.
- Valazza, P.P. Panciani, M. Lanotte, D. Schiffer, L. Annovazzi, V. Caldera, M. Mellai, C. Riganti,
- 801 Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary
- 802 in vitro studies, J. Pharm. Sci. (2014) doi:10.1002/jps.24002.
- 803 [43] T.R. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to
- proliferation and cytotoxicity assay, J. Immunol. Methods 65 (1983) 55–63.
- 805 [44] D. Pandita, A. Ahuja, V. Lather, T. Dutta, T. Velpandian, R.K. Khar, Development,
- 806 characterization and *in vitro* assessement of strearylamine-based lipid nanoparticles of paclitaxel.
- 807 *Pharmazie* 66 (2010) 171-177.
- 808 [45] D. Chirio, M. Gallarate, E. Peira, L. Battaglia, L. Serpe, M. Trotta, Formulation of curcumin-
- loaded solid lipid nanoparticles produced by fatty acids coacervation technique, J. Microencapsul.
- 810 28 (2011) 537-548.
- 811 [46] R. Asasutjarit, S. Lorenzen, S. Sirivichayakul, K. Ruxrungtham, U. Ruktanonchai, G.C.
- 812 Ritthidej, Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential
- and potential for in vitro pHIS-HIV-hugag, Transfection. Pharm. Res. 24 (2007) 1098-1107.
- 814 [47] E. Bolderson, D.J. Richard, B.B. Zhou, K.K. Khanna, Recent advances in cancer therapy
- targeting proteins involved in DNA double-strand break repair, Clin. Cancer Res. 15 (2009) 6314–
- 816 6320.
- 817 [48] B. Pardo, B. Gómez-González, A. Aguilera, DNA repair in mammalian cells: DNA double-
- strand break repair: how to fix a broken relationship, Cell. Mol. Life Sci. 66 (2009) 1039–1056.
- 819 [49] T.C. Johannessen, R. Bjerkvig, B.B. Tysnes, DNA repair and cancer stem-like cells--potential
- partners in glioma drugresistance?, Cancer Treat. Rev. 34 (2008) 558–567.

- 821 [50] S. Agarwal, R. Sane, R. Oberoi, J.R. Ohlfest, W.F. Elmquist, Delivery of molecularly targeted
- therapy to malignant glioma, a disease of the whole brain, Expert Rev. Mol. Med. 13:e17 (2011)
- 823 doi: 10.1017/S1462399411001888.
- 824 [51] L.M. Tai, A.J. Loughlin, D.K. Male, I.A. Romero, P-glycoprotein and breast cancer resistance
- protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-β, J.
- 826 Cereb. Blood F. Met. 29 (2009) 1079-1083.
- 827 [52] A. Salmaggi, A. Boiardi, M. Gelati, A. Russo, C. Calatozzolo, E. Ciusani, F.L. Sciacca, A.
- Ottolina, E.A. Parati, C. La Porta, G. Alessandri, C. Marras, D. Croci, M. De Rossi, GBM-derived
- 829 tumorospheres identify a population of tumor stem-like cells with angiogenic potential and
- enhanced multidrug resistance phenotype, Glia 54 (2006) 850–860.
- 831 [53] E. Nakai, K. Park, T. Yawata, T. Chihara, A. Kumazawa, H. Nakabayashi, K. Shimizu,
- 832 Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from GBM. Cancer
- 833 Invest. 27 (2009) 901–908.

834 FIGURE CAPTIONS

835

- Figure A.1: Anatomical structures composing the BBB. AJs: adherent junctions. TJs: tight
- 837 junctions. ABC: ATP binding cassette transporters.

838

Figure 1: TEM images. a) 2200X magnification; b) 8900X magnification.

840

Figure 2: PTX release plots from nanoparticles using the dialysis method

842

Figure 3: Cou-6 permeability 0.1% dilution. * p < 0.001

844

- Figure 4: Effect of 72 h treatment with increasing doses (100, 500, 1400 nM) of free and 100 nM
- SLN10-encapsulated PTX on NO3 NS (b-e) and NO3 AC (g-k) growth. Control cells (a, f) did not
- receive any treatment. All 200x magnification.

848

- Figure 5: Cytotoxicity of free PTX on NS (A) and AC (B) of NO3 glioma cell line at various
- dosages of drug (20, 100, 500, 1400 nM) after 72 h treatment.

851

- Figure 6: a) cell viability of NO3 NS after 24 h treatment; b) cell viability of NO3 NS after 72 h
- 853 treatment + p < 0.05 vs CTRL; * p < 0.05 PTX-SLN vs SLN; ++ p < 0.01 vs CTRL; ** p < 0.01
- 854 PTX-SLN vs SLN

855

- Figure 7: a) cell viability of NO3 AC after 24 h treatment; b) cell viability of NO3 AC after 72 h
- 857 treatment ++ p < 0.01 vs CTRL; * p < 0.05 PTX-SLN vs SLN;

- Figure 8: TEM of NS after treatment with SLN15 at 15000 x. (a) After 24 h treatment with
- unloaded SLN15. (b) After 6 h treatment with 100 nM PTX-loaded SLN15 (c) After 24 h treatment
- with 100 nM PTX-loaded SLN15 (d) Id, large vacuoles surrounded by a membrane, (e) Id,
- autophagolysosomes, 15000 x. (f) Possible remnants of SLN (20000 x).

- Figure 9: Expression by IF of checkpoint/repair proteins in NO3 glioma cells after 72 h treatment
- 865 with 100 nM PTX-loaded SLN10: p-ATM, 200x (a), γ-H2AX, 200x (b), p-Chk2, 200x (c), p-
- 53BP1, 200x (d), DNA-PKcs, 200x (e), Ku70/80, 200x (f), RAD51, 200x (g) in NS; AC arrested in
- metaphases, DAPI, 200x (j); p-ATM, 200x (k), γ-H2AX foci, 400x (i), p-Chk2, 200x (l), p-53BP1,
- 868 200x (m), DNA-PKcs, 200x (n), RAD51, 200x (o) in AC; nuclei counterstained with DAPI.
- Negative reaction for p-ATM in untreated NS and AC, respectively (upper and lower left inserts of
- panels a and i) and in NS and AC treated with unloaded SLN for 72 h (h and p); nuclei
- counterstained DAPI, 200x.

872

- Figure 10: cytotoxicity against CV17 cells. + p < 0.05 vs CTRL; ++ p < 0.02 vs CTRL;
- 874 +++ p < 0.01 vs CTRL; ++++ p< 0.005 vs CTRL; +++++ p < 0.001 vs CTRL; * p < 0.05 SLN vs
- 875 PTX; ** p < 0.02 SLN vs PTX; *** p < 0.001 SLN vs PTX.

876

- Figure 11: cytotoxicity against O625 cells. + p < 0.05 vs CTRL; ++ p < 0.02 vs CTRL; +++ p < 0.02
- 878 0.01 vs CTRL; ++++ p < 0.005 vs CTRL; +++++ p < 0.001 vs CTRL; * p < 0.05 SLN vs PTX.

879

- Figure 12: cytotoxicity against U87 cells. + p < 0.01 vs CTRL; ++ p < 0.002 vs CTRL; +++ p < 0.002 vs CTRL; ++ p < 0.002 vs CTRL; + p < 0.002
- 881 0.005 vs CTRL; * p < 0.05 SLN vs PTX; *** p < 0.02 SLN vs PTX; *** p < 0.001 SLN vs PTX.

- Figure 13: cytotoxicity against hCMEC/D3 cells. + p < 0.01 vs CTRL; ++ p < 0.005 vs CTRL
- * p < 0.05 SLN vs PTX; ** p < 0.002 SLN vs PTX.

SLN	Na-BA* (mg)	PVA 9000 (mg)	PTX (mg)	CHOL (mg)	ST (mg)	GCS (mg)	Mean diameter (nm) (PDI)	Zeta Potential (mV)
0	53	37.5	3	-	-	-	299.2 ± 0.3 (0.053)	- 3.04 ± 0.56
1	53	37.5	3	0.5	-	-	381.3 ± 20.4 (0.152)	- 3.30 ± 0.47
2	53	37.5	4.5	0.5	-	-	386.4 ± 12.3 (0.167)	- 3.34 ± 0.79
3	53	37.5	6	0.5	-	-	383.8 ± 23.2 (0.085)	- 3.41 ± 0.60
4	53	37.5	3	-	3	-	345.6 ± 9.7 (0.089)	7.85 ± 0.91
5	53	37.5	3	-	6	-	537.7 ± 13.5 (0.105)	14.37 ± 1.52
6	53	37.5	3	0.5	3	-	581.0 ± 61.1 (0.201)	8.03 ± 0.70
7	53	25	3	0.5	3	-	507.0 ± 10.5 (0.099)	10.19 ± 0.69
8	53	37.5	3	0.75	3	-	579.6 ± 7.7 (0.115)	10.40 ± 1.14
9	53	37.5	4.5	0.5	3	-	548.6 ± 20.2 (0.130)	9.07 ± 2.45
10	53	37.5	6	0.5	3		984.9 ± 93.6 (0.103)	7.65 ± 0.85
11	53	37.5	6	-	-	10	553.5 ± 5.7 (0.196)	16.90 ± 4.13
12	53	37.5	6	-	-	16	488.4 ± 19.3 (0.213)	23.79 ± 1.81
13	53	50	6	-	-	10	469.6 ± 3.8 (0.202)	15.46 ± 2.32
14	53	100	6	-	-	10	624.3 ± 16.1 (0.205)	15.64 ± 3.12
15	53	37.5	4.5	0.5	-	10	462.7 ± 32.3 (0.227)	18.21 ± 1.67
16	53	37.5	6	0.5	-	10	476.4 ± 8.4 (0.196)	20.28 ± 1.10
17	53	50	6	0.5	-	10	374.5 ± 4.8 (0.232)	19.56 ± 1.73

887 Table 1

SLN	PTX EE%	PTX LOADING (µg PTX/mg BA)
0	78 ± 4	47 ± 2
1	85 ± 5	50 ± 3
2	89 ± 3	80 ± 3
3	90 ± 3	108 ± 4
4	70 ± 6	42 ± 4
5	25 ± 3	16 ± 2
6	87 ± 4	52 ± 2
7	98 ± 2	60 ± 1
8	65 ± 6	40 ± 4
9	92 ± 4	82 ± 3
11	77 ± 2	92 ± 2
12	81 ± 4	98 ± 5
13	52 ± 5	62 ± 6
14	24 ± 3	28 ± 3
15	83 ± 4	74 ± 3
16	83 ± 3	100 ± 4
17	75 ± 5	90 ± 6

890 Table 2

		SLN 9	SLN 15	SLN 16	SLN 17
	Size (nm)	682.4 ± 15.1	783.2 ± 74.3	554.2 ± 9.5	500.1 ± 6.4
7 days	%EE	92 ± 3	81 ± 2	80 ± 2	74 ± 3
7 days	Zeta potential (mV)	9.15 ± 0.85	13.4 ± 0.9	15.9 ± 2.8	18.3 ± 1.6
	Size (nm)	1500.0 ± 21.6	799.7 ± 63.2	598.1 ± 14.6	599.2 ± 9.5
30 days	%EE	91 ± 4	80 ± 3	79 ± 3	73 ± 2
30 days	Zeta potential (mV)	9.05 ± 0.54	11.6 ± 1.4	14.5 ± 3.3	14.4 ± 3.1
	Size (nm)	1536.8 ± 39.2	933.8 ± 17.9	669.8 ± 27.3	686.1 ± 12.4
60 days	%EE	89 ± 4	80 ± 3	71 ± 2	73 ± 2
oo days	Zeta potential (mV)	9.07 ± 0.65	10.7 ± 2.1	13.9 ± 3.4	12.9 ± 4.1

893 Table 3

	SLN 9	SLN 15	SLN 16	SLN 17
Mean diameter (nm)	842.0 ± 17.9	632.4 ± 18.4	592.3 ± 18.0	408.4 ± 5.8
Zeta potential (mV)	8.66 ± 1.02	18.56 ± 1.34	19.68 ± 1.98	19.87 ± 1.45
PTX EE%	88 ± 3	81 ± 2	83 ± 2	89 ± 3

895 Table 4




Figure 1a and 1b Chirio et al




Figure 2
Chirio et al




Figure 3
Chirio et al





Figure 4
Chirio et al







Figure 5
Chirio et al







Figure 6
Chirio et al






Figure 7
Chirio et al




Figure 8
Chirio et al




Figure 9
Chirio et al




Figure 10
Chirio et al




Figure 11
Chirio et al




Figure 12 Chirio et al




Figure 13
Chirio et al